Literature DB >> 32952737

Pathologic Shear and Elongation Rates Do Not Cause Cleavage of Von Willebrand Factor by ADAMTS13 in a Purified System.

Maria Bortot1,2, Alireza Sharifi3, Katrina Ashworth1, Faye Walker1, Allaura Cox1, Katherine Ruegg4, Nathan Clendenen5, Keith B Neeves1,2, David Bark1,3,6, Jorge Di Paola7.   

Abstract

INTRODUCTION: Pathological flows in patients with severe aortic stenosis are associated with acquired von Willebrand syndrome. This syndrome is characterized by excessive cleavage of von Willebrand factor by its main protease, A Disintegrin and Metalloproteinase with a Thrombospondin Type 1 Motif, Member 13 (ADAMTS13) leading to decreased VWF function and mucocutaneous bleeding. Aortic valve replacement and correction of the flow behavior to physiological levels reverses the syndrome, supporting the association between pathological flow and acquired von Willebrand syndrome. We investigated the effects of shear and elongational rates on von Willebrand factor cleavage in the presence of ADAMTS13.
METHODS: We identified acquired von Willebrand syndrome in five patients with severe aortic stenosis. Doppler echography values from these patients were used to develop three computational fluid dynamic (CFD) aortic valve models (normal, mild and severe stenosis). Shear, elongational rates and exposure times identified in the CFD simulations were used as parameters for the design of microfluidic devices to test the effects of pathologic shear and elongational rates on the structure and function of von Willebrand factor.
RESULTS: The shear rates (0-10,000s-1), elongational rates (0-1000 s-1) and exposure times (1-180 ms) tested in our microfluidic designs mimicked the flow features identified in patients with aortic stenosis. The shear and elongational rates tested in vitro did not lead to excessive cleavage or decreased function of von Willebrand factor in the presence of the protease.
CONCLUSIONS: High shear and elongational rates in the presence of ADAMTS13 are not sufficient for excessive cleavage of von Willebrand Factor. © Biomedical Engineering Society 2020.

Entities:  

Keywords:  Acquired von Willebrand syndrome; Aortic stenosis; Elongational flow; Non-surgical bleeding; Reynolds number; Shear rate

Year:  2020        PMID: 32952737      PMCID: PMC7479076          DOI: 10.1007/s12195-020-00631-2

Source DB:  PubMed          Journal:  Cell Mol Bioeng        ISSN: 1865-5025            Impact factor:   2.321


  56 in total

1.  Transcatheter aortic valve implantation leads to a restoration of von Willebrand factor (VWF) abnormalities in patients with severe aortic stenosis - Incidence and relevance of clinical and subclinical VWF dysfunction in patients undergoing transfemoral TAVI.

Authors:  Alexander Sedaghat; Hannah Kulka; Jan-Malte Sinning; Nora Falkenberg; Julia Driesen; Barbara Preisler; Christoph Hammerstingl; Georg Nickenig; Bernd Pötzsch; Johannes Oldenburg; Hans-Jörg Hertfelder; Nikos Werner
Journal:  Thromb Res       Date:  2017-01-07       Impact factor: 3.944

2.  Numerical simulation of patient-specific left ventricular model with both mitral and aortic valves by FSI approach.

Authors:  Boyang Su; Liang Zhong; Xi-Kun Wang; Jun-Mei Zhang; Ru San Tan; John Carson Allen; Soon Keat Tan; Sangho Kim; Hwa Liang Leo
Journal:  Comput Methods Programs Biomed       Date:  2013-11-27       Impact factor: 5.428

3.  Extensional flow of blood analog solutions in microfluidic devices.

Authors:  P C Sousa; F T Pinho; M S N Oliveira; M A Alves
Journal:  Biomicrofluidics       Date:  2011-03-17       Impact factor: 2.800

4.  Shear-dependent changes in the three-dimensional structure of human von Willebrand factor.

Authors:  C A Siedlecki; B J Lestini; K K Kottke-Marchant; S J Eppell; D L Wilson; R E Marchant
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

5.  FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.

Authors:  Koichi Kokame; Yuko Nobe; Yoshihiro Kokubo; Akira Okayama; Toshiyuki Miyata
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

6.  Zinc and calcium ions cooperatively modulate ADAMTS13 activity.

Authors:  Patricia J Anderson; Koichi Kokame; J Evan Sadler
Journal:  J Biol Chem       Date:  2005-11-11       Impact factor: 5.157

7.  A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura.

Authors:  Yue Han; Juan Xiao; Erica Falls; X Long Zheng
Journal:  Transfusion       Date:  2011-01-20       Impact factor: 3.157

8.  Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress.

Authors:  Kyuhwan Shim; Patricia J Anderson; Elodee A Tuley; Erin Wiswall; J Evan Sadler
Journal:  Blood       Date:  2007-09-27       Impact factor: 22.113

9.  Fluid-Structure Interaction Simulation of Prosthetic Aortic Valves: Comparison between Immersed Boundary and Arbitrary Lagrangian-Eulerian Techniques for the Mesh Representation.

Authors:  Alessandra M Bavo; Giorgia Rocatello; Francesco Iannaccone; Joris Degroote; Jan Vierendeels; Patrick Segers
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

10.  Effects of anti-β2GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity.

Authors:  Christopher J Ng; Keith R McCrae; Katrina Ashworth; Lucas J Sosa; Venkaiah Betapudi; Marilyn J Manco-Johnson; Alice Liu; Jing-Fei Dong; Dominic Chung; Tara C White-Adams; José A López; Jorge Di Paola
Journal:  Res Pract Thromb Haemost       Date:  2018-03-24
View more
  1 in total

1.  Predicting pathological von Willebrand factor unraveling in elongational flow.

Authors:  Sagar Kania; Alparslan Oztekin; Xuanhong Cheng; X Frank Zhang; Edmund Webb
Journal:  Biophys J       Date:  2021-03-16       Impact factor: 4.033

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.